

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

INSITE VISION INCORPORATED, INSPIRE PHARMACEUTICALS, INC. PFIZER INC., <p align="center">Plaintiffs,</p> <p align="center">v.</p> SANDOZ INC., SANDOZ GMBH, SANDOZ INDUSTRIAL PRODUCTS S.A., <p align="center">Defendants</p>	Civil Action No.: 11-03080-MLC-LHG
---	---

RECEIVED

JUL - 8 2012

AT 8:30 ^M
WILLIAM T. WALSH CLERK

ORDER OF CLAIM CONSTRUCTION

THIS MATTER HAVING COME BEFORE THE COURT for construction of disputed terms of U.S. Patent No. 6,861,411 (“the ‘411 Patent”), 6,239,113 (“the ‘113 Patent”), 6,569,443 (“the ‘443 Patent”) and 7,056,893 (“the ‘893 Patent”); with a hearing conducted on June 27, 2012 and the Court having considered all submissions of the parties in support thereof; and for good cause shown;


IT IS this 8th day of ~~July~~ ^{AUGUST}, 2012;

IT IS HEREBY ORDERED THAT the following terms of the claims of the Patents are hereby construed as follows:

Patent	Claim Term	Construction
‘411 Patent	“ocular infection treating amount”	<i>Amount sufficient to remediate ocular infection.</i>
‘411 Patent	“administered once daily”	<i>A regimen that includes once daily dosing.</i>
‘113 Patent	“topically applying”	<i>Supplying to the external eye surface.</i>
‘443 Patent; ‘893 Patent	“depot”	<i>A source of azalide antibiotic that is not rapidly removed by tears or other eye</i>

		<i>clearance mechanisms.</i>
'893 Patent	"administering"	<i>To give remedially.</i>
'893 Patent	"one or two doses per day"	<i>A quantity of a therapeutic agent taken one or two times per day.</i>

SO ORDERED:



Honorable Mary L. Cooper, U.S.D.J.